PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells

Li, Miao; Shi, Fangfang; Xiong, Fei; Wu, Songyan; Wu, Di; Pan, Meng; Luo, Shouhua; Gu, Ning; Dou, Jun

doi:10.1177/1535370216685008

Cited by 15 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum protein binding and associated complement-dependent activation are reported to be dependent on nanoliposome size [ 45 ]. These two mechanisms together increase the rate of particle clearance in vivo [ 46 ]. Nanoliposomes with diameters less than 50–80 nm are subject to significantly lower MPS-dependent clearance in humans.…”

Section: Impact Of Particle Sizementioning

confidence: 99%

See 1 more Smart Citation

Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems

et al. 2018

View full text Add to dashboard Cite

Lipid-based drug delivery systems, or lipidic carriers, are being extensively employed to enhance the bioavailability of poorly-soluble drugs. They have the ability to incorporate both lipophilic and hydrophilic molecules and protecting them against degradation in vitro and in vivo. There is a number of physical attributes of lipid-based nanocarriers that determine their safety, stability, efficacy, as well as their in vitro and in vivo behaviour. These include average particle size/diameter and the polydispersity index (PDI), which is an indication of their quality with respect to the size distribution. The suitability of nanocarrier formulations for a particular route of drug administration depends on their average diameter, PDI and size stability, among other parameters. Controlling and validating these parameters are of key importance for the effective clinical applications of nanocarrier formulations. This review highlights the significance of size and PDI in the successful design, formulation and development of nanosystems for pharmaceutical, nutraceutical and other applications. Liposomes, nanoliposomes, vesicular phospholipid gels, solid lipid nanoparticles, transfersomes and tocosomes are presented as frequently-used lipidic drug carriers. The advantages and limitations of a range of available analytical techniques used to characterize lipidic nanocarrier formulations are also covered.

show abstract

Section: Impact Of Particle Sizementioning

confidence: 99%

“…The presence of PEG polymer coating on the surface of the lipidic carriers has been shown to reduce their uptake by phagocytic cells. As a result, these long-circulating carriers (also known as stealth vesicles) attain longer blood circulation times [ 45 , 46 ].…”

Section: Impact Of Particle Sizementioning

confidence: 99%

Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The bound DNA fragments were then isolated by ChIP reactions and subjected to PCR using primers specific to the promoters of CD44 or ESA. The primers used in the ChIP assay are listed in Additional file 4: Supplementary Table S5 [24,25].…”

Section: Chromatin Immunoprecipitation (Chip)-pcr Assaymentioning

confidence: 99%

MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth

Pan

You

et al. 2020

Breast Cancer Res

Self Cite

View full text Add to dashboard Cite

Background: Breast cancer stem cells (BCSCs) are typically seed cells of breast tumor that initiate and maintain tumor growth. MiR-7, as a cancer inhibitor, decreases the BCSC subset and inhibits tumor progression through mechanisms that remain unknown. Methods: We examined miR-7 expression in breast cancer and developed a BCSC-driven xenograft mouse model, to evaluate the effects of miR-7 overexpression on the decrease of the BCSC subset in vitro and in vivo. In addition, we determined how miR-7 decreased the BCSC subset by using the ALDEFLUOR, lentivirus infection, dual-luciferase reporter, and chromatin immunoprecipitation-PCR assays. Results: MiR-7 was expressed at low levels in breast cancer tissues compared with normal tissues, and overexpression of miR-7 directly inhibited lncRNA XIST, which mediates the transcriptional silencing of genes on the X chromosome, and reduced epithelium-specific antigen (ESA) expression by increasing miR-92b and inhibiting slug. Moreover, miR-7 suppressed CD44 and ESA by directly inhibiting the NF-κB subunit RELA and slug in breast cancer cell lines and in BCSC-driven xenografts, which confirmed the antitumor activity in mice injected with miR-7 agomir or stably infected with lenti-miR-7. Conclusions: The findings from this study uncover the molecular mechanisms by which miR-7 inhibits XIST, modulates the miR-92b/Slug/ESA axis, and decreases the RELA and CD44 expression, resulting in a reduced BCSC subset and breast cancer growth inhibition. These findings suggest a potentially targeted treatment approach to breast cancer.

show abstract

“…MASM inhibits hepatic cancer stem-like cells and markedly reduces the number of surviving cancer stem-like cells in the tumors. Isoharringtonine had inhibitory effects on BCSCs in breast cancer cell lines via inhibition of the STAT3/Nanong pathway.Berberis libanotica Ehrenb extract were sufficient to remove the self-renewal ability of highly resistant CSCs [ 97 , 99 – 101 , 108 , 109 , 111 , 112 ] TAAs IL-4, GFAP Stachydrine suppresses proliferation and colony formation in Pilocytic astrocytoma cells through downregulated CXCR4 transcription and enhancing IκBα-based NF-κB inhibition. Palmatine suppresses glutamine-mediated changes in GLI signaling in PCCs while induces apoptosis by inhibition of survivin to disrupt reciprocal interaction between PSCs and PCCs in the TME Conophylline reduced liver and pancreatic fibrosis by suppression of stellate cells [ 30 , 115 , 119 , 121 ] Angiogenesis VEGF α-solanine treatment significantly reduce the expression of VEGF and endothelial cell tube formation Berberine prevents the expression of HIF-1 to inhibit tumor-induced angiogenesis in hypoxic gastric cancer cells、HCC cells and human umbilical vein endothelial cells.…”

Section: Introductionmentioning

confidence: 99%

Tumor microenvironment: a prospective target of natural alkaloids for cancer treatment

Luo

Yin

et al. 2021

Cancer Cell Int

View full text Add to dashboard Cite

Malignant tumor has become one of the major diseases that seriously endangers human health. Numerous studies have demonstrated that tumor microenvironment (TME) is closely associated with patient prognosis. Tumor growth and progression are strongly dependent on its surrounding tumor microenvironment, because the optimal conditions originated from stromal elements are required for cancer cell proliferation, invasion, metastasis and drug resistance. The tumor microenvironment is an environment rich in immune/inflammatory cells and accompanied by a continuous, gradient of hypoxia and pH. Overcoming immunosuppressive environment and boosting anti-tumor immunity may be the key to the prevention and treatment of cancer. Most traditional Chinese medicine have been proved to have good anti-tumor activity, and they have the advantages of better therapeutic effect and few side effects in the treatment of malignant tumors. An increasing number of studies are giving evidence that alkaloids extracted from traditional Chinese medicine possess a significant anticancer efficiency via regulating a variety of tumor-related genes, pathways and other mechanisms. This paper reviews the anti-tumor effect of alkaloids targeting tumor microenvironment, and further reveals its anti-tumor mechanism through the effects of alkaloids on different components in tumor microenvironment.

show abstract

PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells

Cited by 15 publications

References 30 publications

Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems

Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems

MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth

Tumor microenvironment: a prospective target of natural alkaloids for cancer treatment

Contact Info

Product

Resources

About